RAPP trades 190.2% below Wall Street's consensus target of $67.91.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RAPP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) has a Wall Street consensus price target of $67.91, based on estimates from 8 covering analysts. With the stock currently trading at $23.40, this represents a potential upside of +190.2%. The company has a market capitalization of $1.12B.
Analyst price targets range from a low of $47.00 to a high of $91.00, representing a 65% spread in expectations. The median target of $70.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RAPP trades at a trailing P/E of -7.4x. Analysts expect EPS to grow -5.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PTCTPTC Therapeutics, Inc. | $5.0B | $60.23 | $102.89 | +70.8% | Buy | 114.5x | 26 |
ACADACADIA Pharmaceuticals Inc. | $3.1B | $17.83 | $30.05 | +68.5% | Buy | 28.6x | 37 |
PRAXPraxis Precision Medicines, Inc. | $8.5B | $305.19 | $611.69 | +100.4% | Buy | — | 18 |
INVAInnoviva, Inc. | $1.4B | $18.40 | $38.00 | +106.5% | Buy | 7.6x | 11 |
NKTRNektar Therapeutics | $1.2B | $34.42 | $121.33 | +252.5% | Buy | — | 33 |
LGNDLigand Pharmaceuticals Incorporated | $6.0B | $298.71 | $342.00 | +14.5% | Buy | 31.4x | 18 |
ARVNArvinas, Inc. | $437M | $6.77 | $14.00 | +106.9% | Buy | 95.0x | 26 |
AXSMAxsome Therapeutics, Inc. | $6.9B | $134.00 | $279.25 | +108.4% | Buy | — | 27 |
SRRKScholar Rock Holding Corporation | $5.8B | $48.00 | $71.30 | +48.5% | Buy | — | 14 |
LLYEli Lilly and Company | $1.3T | $1382.54 | $1445.12 | +4.5% | Buy | 39.1x | 46 |
Quick answers to the most common questions about buying RAPP stock.
The consensus Wall Street price target for RAPP is $67.91, representing 190.2% upside from the current price of $23.4. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RAPP has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $67.91 implies 190.2% upside from current levels.
RAPP's current price is $23.4 with a consensus target of $67.91 (190.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $91 for RAPP, while the most conservative target is $47. The consensus of $67.91 represents the median expectation. These targets typically reflect 12-month expectations.
RAPP is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RAPP stock forecast based on 8 Wall Street analysts shows a consensus price target of $67.91, with estimates ranging from $47 (bear case) to $91 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on RAPP, with a "Buy" consensus rating and $67.91 price target (190.2% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RAPP analyst price targets range from $47 to $91, a 65% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $67.91 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.